Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Fortress Biotech Q3 2026 Results: Net Loss of $5.84M

Fortress Biotech reported a significant net income of $129.5 million for the nine months ended September 30, 2026, primarily driven by a $158.9 million gain on the sale of a priority review voucher. This represents a substantial turnaround from the $27.5 million net loss in the prior year period, while total assets grew to $280.2 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue19.217.6
Profit before tax-8.38.9
Net income-5.85.8
EPS (diluted, $ a share)$-0.23$0.11

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+8.7%
Operating margin-37.5%
Source

10-Q filed with the SEC, NASDAQ: FBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Fortress Biotech, Inc.: key numbers

Share price
$1.71Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Fortress Biotech, Inc.

All →
8:06 AM ET 8-K
Financial Results

Fortress Biotech Financial Results

Fortress Biotech reported Q3 2026 financial results with total net revenue increasing 9% year-over-year to $19.2 million. During the quarter, the company repaid its Oaktree credit facility in full, leaving it with no outstanding debt at the parent level, and in-licensed FB-607 for the treatment of IBS-D.

Term
Q3 2026

“The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”).”

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer

“With our growing royalty income from ZYCUBO® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
4:31 PM ET 8-K
Deal Termination

Fortress Biotech Deal Termination with Oaktree Fund Administration, LLC

Fortress Biotech repaid in full its remaining $15.0 million outstanding principal under its senior secured credit agreement with Oaktree Fund Administration, LLC. Upon payment of the principal, accrued interest, and a prepayment fee, all liens were released and the credit agreement was automatically terminated. This action eliminates the company's debt obligations under the Oaktree facility.

Counterparty
Oaktree Fund Administration, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.